Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal
prognosis. Survival outcomes have remained static in recent decades despite treatment …

Simple Summary Acute lymphoblastic leukemia (ALL) is the most common cancer among
pediatric patients. Thanks to the introduction of revolutionary treatment methods and …

The last decade has seen a significant leap in our understanding of the wide range of
genetic lesions underpinning acute lymphoblastic leukaemia (ALL). Next generation …

Purpose: To date, there are no systemic treatment options for patients with recurrent or
refractory meningioma. Experimental Design: To identify effective drugs, we performed a …

Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute
lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive …

In pediatric acute lymphoblastic leukemia (ALL), mutations/deletions affecting the TP53
gene are rare at diagnosis. However, at relapse about 12% of patients show TP53 …

Background Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia
(ALL) have poor outcomes. There is an urgent need to identify novel agents to improve …

Acute lymphocytic leukemia is a hematological malignancy that primarily affects children.
Long-term chemotherapy is effective, but always causes different toxic side effects. With the …

Objectives T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) are
highly malignant and aggressive hematologic tumors for which there is no standard first-line …

Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma
(PTCL). However, the timing of romidepsin administration remains controversial. The …